Hikma Flyer Global 2016

Hikma Pharmaceuticals
Trusted to deliver better health
About Hikma
Our operations
29 manufacturing facilities in 11
countries - FDA approved facilities in 5
countries
Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK)
(NASDAQ Dubai: HIK) is a fast growing
multinational pharmaceutical group which was
founded in 1978 in Jordan
Hikma develops, manufactures and markets a
broad range of branded, non-branded generic
and in-licensed products
Hikma operates in the US, Europe and across
the MENA region
Germany
Portugal
• 6th largest generic company in the US by value, after the
acquisition of Roxane labs
Tunisia
USA
Italy
Algeria
Jordan
Saudi Arabia
Morocco
Sudan
Egypt
• 3rd largest supplier of injectables in the US by volume
• 5th largest pharmaceutical company in the MENA
Hikma is committed to the highest quality
manufacturing with multiple FDA approved
facilities
Hikma Markets
Hikma's global team is currently over 8000
employees
R&D Centres
Manufacturing Plants
Our track record
1500
1,489
Group revenues ($ million)
1400
1,365
1,440
Financial highlights
1300
1200
1,108.7
$ (million)
2015
2014
Revenue
1,440
1,489
Adjusted operating profit
409
427
Adjusted profit attributable
to shareholders
286
299
143.7
151
32
32
1100
1000
918
900
800
730.9
700
637
581
600
500
449
400
317
300
200
100
0
51
67
76
90
99
105
138
188
212
Adjusted basic earnings
per share (cents)
262
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Dividend per share (cents)
Our shares
Primary listing
London Stock Exchange (HIK)
NASDAQ Dubai (HIK); 1 GDR=2 Ordinary
Secondary listings
OTC (HIK): 1 ADR=2 Ordinary
Market cap
£4.6 billion ($6.4 billion)*
Reporting currency
US Dollars ($)
Free float
71% (90% institutional investors)
*Based on closing price of £19.80 and an issued share capital of around 240 million ordinary shares as of 31st March 2016
Business development enquiries:
Osama Nabulsi
VP Business Development and
Alliance Management
Hikma Pharmaceuticals
P.O. Box 182400
Amman 11118, Jordan
onabulsi@hikma.com
Investor & general enquiries:
Susan Ringdal
VP Corporate Strategy and
Investor Relations
Hikma Pharmaceuticals
13 Hanover Square
London W1S 1HW, UK
susan@hikma.uk.com
Date:
March 2016
Website:
www.hikma.com
Hikma Pharmaceuticals
Trusted to deliver better health
Our businesses
Branded
Products
377 branded products
Markets
MENA
Top products
Amoclan®
Blopress®
Omnicef®
Prograf®
Suprax®
Injectables
185 injectable products
MENA
Europe
US
Argatroban
Fentanyl
Glycopyrrolate
Nicardipine
Phenylephrine
$710 m
Generics
26 non-injectable products
US
Butalbital
Captopril
Colchicine
Doxycycline
Prednisone
$151 m
2015 Revenue
$570 m
Our strategy
Strengthening our position as a leading global injectables manufacturer
Developing our portfolio for non-injectable generics in the US market
Leveraging our position as a leading pharmaceutical manufacturer in MENA
Enhancing our product portfolio and pipeline through internal R&D and external partnerships
Maintaining high-quality manufacturing facilities and efficient operations
Developing a highly skilled and effective workforce
Our partnerships
Reputation for quality products and
long standing relationships with
global licensing partners
Over 2000 sales and marketing
professionals globally
Mitsubishi Tanabe Pharma
Excellent knowledge of registration
processes and local health
authorities
Strong brand recognition and
partner of choice in the MENA
region
Business development enquiries:
Osama Nabulsi
VP Business Development and
Alliance Management
Hikma Pharmaceuticals
P.O. Box 182400
Amman 11118, Jordan
onabulsi@hikma.com
Investor & general enquiries:
Susan Ringdal
VP Corporate Strategy and
Investor Relations
Hikma Pharmaceuticals
13 Hanover Square
London W1S 1HW, UK
susan@hikma.uk.com
Date:
March 2016
Website:
www.hikma.com